echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AbbVie JAK inhibitor reaches two primary endpoints of Phase 3 clinical trials

    AbbVie JAK inhibitor reaches two primary endpoints of Phase 3 clinical trials

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 7, 2021, AbbVie announced that its oral JAK inhibitor upadacitinib (upadacitinib, English trade name Rinvoq) has been carried out in two adult patients with axial spondylitis (axSpA).
    Phase clinical trials reached the primary endpoint

    .

    The results of two phase 3 clinical trials showed that at week 14, whether in patients with non-radiological axial spondyloarthritis (nr-axSpA), or in patients with active ankylosing spondylitis (AS ), compared with placebo, more patients in the upatinib group achieved a 40 response of the International Spondyl Arthritis Society (ASAS)
    .
    Patients received statistically significant reductions in symptoms, including back pain and inflammation, as well as improvements in physical function and disease activity

    .
    Axial spondyloarthritis is a chronic inflammatory disease that affects the spine, which can cause back pain, restricted mobility, and structural damage

    .

    In patients with active ankylosing spondylitis (AS)

    45% of the patients in the upatinib group met the ASAS40 standard, which was significantly better than the placebo group (18%)
    .

    In addition, upatinib also reached multiple secondary endpoints of the trial.
    The specific results are shown in the figure below

    .

    The safety data is consistent with previous studies, and no new risks have been found
    .

    Picture source: reference [1]

    In patients with active non-radiological axial spondyloarthritis

    45% of the patients in the upatinib group met the ASAS40 standard, which was significantly higher than the placebo group (23%)
    .

    In addition, upatinib also reached multiple secondary endpoints of the trial.
    The specific results are shown in the figure below

    .

    Picture source: reference [2]

    Upatinib was discovered and developed by AbbVie scientists.
    It is a selective and reversible JAK inhibitor that is taken orally once a day

    .
    In August 2019, it was approved by the U.
    S.
    FDA for the treatment of moderate to severe adult patients with active rheumatoid arthritis who are inadequate or intolerant to methotrexate

    .
    The JAK protein family mediates the signal transduction of a variety of inflammatory factors

    .
    Upatinib has obtained positive results in phase 3 clinical trials for the treatment of rheumatoid arthritis, atopic dermatitis, Crohn's disease, psoriatic arthritis and other inflammatory diseases

    .

    Reference materials:

    [1] AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis.
    Retrieved October 7, 2021, from https:// -met-primary-and-all-ranked-secondary-endpoints-in-phase-3-study-in-ankylosing-spondylitis-301395108.
    html

    [2] AbbVie's upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis.
    Retrieved October 7, 2021, from https:// upadacitinib-rinvoq-met-primary-and-most-ranked-secondary-endpoints-in-phase-3-study-for-non-radiographic-axial-spondyloarthritis-301395109.
    html

    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.